OncoMatch/Clinical Trials/NCT02259556
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Is NCT02259556 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CART30 for hodgkin's lymphoma.
Treatment: CART30 — Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors. In this trial, CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma will be treated by CD30-specific CART cells (CART30).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD30 overexpression (positive)
CD30+ Hodgkin lymphoma and Non-Hodgkin lymphoma
Prior therapy
Must have received: autologous stem cell transplant — relapsed
relapsing after autologous stem-cell transplantation (ASCT)
Must have received: cytotoxic chemotherapy — refractory
refractory to 2 multidrug regimens
Must have received: anti-CD30 antibody — refractory
refractory to ... anti-CD30 antibody treatment
Cannot have received: anti-CD30 antibody
Exception: within recent 6 weeks
Receive anti-CD30 antibody-based therapy within recent 6 weeks
Lab requirements
Kidney function
Creatinine <2.5mg/dl
Liver function
ALT (alanine aminotransferase)/AST (aspartate aminotransferase) <3 fold normal; Bilirubin <2.5mg/dl
Creatinine <2.5mg/dl. ALT (alanine aminotransferase)/AST (aspartate aminotransferase) <3 fold normal. Bilirubin <2.5mg/dl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify